Molecular chaperones as therapeutic targets to counteract proteostasis defects

Journal of Cellular Physiology

Volumn 227, Issue 3, 2012, Pages 1226-1234

  Cattaneo, Monica ^a   Dominici, Roberto ^b   Cardano, Marina ^c,d   Diaferia, Giuseppe ^c   Rovida, Ermanna ^a   Biunno, Ida ^a  

^a CNR   (Italy)

^b Ospedale G Fornaroli   (Italy)

^c Integrated Systems Engineering srl   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHAPERONE; HEAT SHOCK PROTEIN 100; HEAT SHOCK PROTEIN 40; HEAT SHOCK PROTEIN 60; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; TETRATRICOPEPTIDE REPEAT PROTEIN; TRANSMEMBRANE CONDUCTANCE REGULATOR;

ALZHEIMER DISEASE; AMINO ACID SEQUENCE; AMYOTROPHIC LATERAL SCLEROSIS; CARCINOGENESIS; ENDOPLASMIC RETICULUM STRESS; FABRY DISEASE; HUNTINGTON CHOREA; HYDROPHOBICITY; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN ANALYSIS; PROTEIN CONFORMATION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN HOMEOSTASIS; PROTEIN METABOLISM; PROTEIN SECONDARY STRUCTURE; PROTEIN STABILITY; PROTEIN SYNTHESIS; PROTEIN TARGETING; REVIEW; SEQUENCE ANALYSIS; STRUCTURE ACTIVITY RELATION; TETRATRICOPEPTIDE REPEAT; THERMODYNAMICS; UNFOLDED PROTEIN RESPONSE; UPREGULATION;

DRUG DELIVERY SYSTEMS; HUMANS; MOLECULAR CHAPERONES; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROTEOSTASIS DEFICIENCIES;

EID: 84155184186     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.22856     Document Type: Review

References (84)

1. Agashe VR, Shastry MC, Ugdaonkar JB. 1995. Initial hydrophobic collapse in the folding of barstar. Nature 377: 754-757.
2. Anfinsen CB. 1973. Priciples that govern the folding of protein chains. Science 181: 223-230.
3. Ardley HC, Hung CC, Robinson PA. 2005. The aggravating role of the ubiquitin-proteasome system in neurodegeneration. FEBS Lett 579: 571-576.
4. Backer JM, Krivoshein AV, Hamby CV, Pizzonia J, Gilbert KS, Ray YS, Brand H, Paton AW, Paton JC, Backer MV. 2009. Chaperone-targeting cytotoxin and endoplasmic reticulum stress-inducing drug synergize to kill cancer cells. Neoplasia 11: 1165-1173.
5. Balasenthil S, Chen N, Lott ST, Chen J, Carter J, Grizzle WE, Frazier ML, Sen S, Killary AM. 2010. A migration signature and plasma biomarker panel for pancreatic adenocarcinoma. Cancer Prev Res 4: 137-149.
6. Baldwin RL, Rose GD. 1999. Is protein folding hierarchic? II. Folding intermediates and transition states. Trends Biochem Sci 24: 77-83.
7. Barberis MC, Roz E, Biunno I. 2006. SEL1L expression in prostatic intraepithelial neoplasia and adenocarcinoma: An immunohistochemical study. Histopathology 48: 614-616.
8. Biunno I, Cattaneo M, Orlandi R, Canton C, Biagiotti L, Ferrero S, Barberis M, Pupa SM, Scarpa A, Menard S. 2006. SEL1L a multifaceted protein playing a role in tumor progression. J Cell Physiol 208: 23-38.
9. Calderwood SK, Khaleque MA, Sawyer DB, Ciocca DR. 2006. Heat shock proteins in cancer: Chaperones of tumorigenesis. Trends Biochem Sci 31: 164-172.
10. Cardano M, Diaferia GR, Cattaneo M, Dessi SS, Long Q, Conti L, Deblasio P, Cattaneo E, Biunno I. 2011. mSEL-1L (suppressor/enhancer LIN12 like) levels influence murine neural stem cell self-renewal and lineage commitment. J Biol Chem 286: 18708-18719.
11. Cattaneo M, Canton C, Albertini A, Biunno I. 2004. Identification of a region within SEL1L protein required for tumour growth inhibition. Gene 326: 149-156.
12. Cattaneo M, Lotti LV, Martino S, Alessio M, Conti A, Bachi A, Mariani-Costantini R, Biunno I. 2011. Secretion of novel SEL1L endogenous variants is promoted by ER stress/UPR via endosomes and shed vesicles in human cancer cells. PLoS One 6: e17206.
13. Cattaneo M, Orlandini S, Beghelli S, Moore PS, Sorio C, Bonora A, Bassi C, Talamini G, Zamboni G, Orlandi R, Ménard S, Bernardi LR, Biunno I, Scarpa A. 2003. SEL1L expression in pancreatic adenocarcinoma parallels SMAD4 expression and delays tumor growth in vitro and in vivo. Oncogene 22: 6359-6368.
14. Demand J, Lüders J, Höhfeld J. 1998. The carboxy-terminal domain of Hsc70 provides binding sites for a distinct set of chaperone cofactors. Mol Cell Biol 18: 2023-2028.
15. Dill KA, Ozkan SB, Weikl TR, Chodera JD, Voelz VA. 2007. The protein folding problem: When will it be solved? Curr Opin Struct Biol 17: 342-346.
16. Dill KA, Ozkan SB, Shell MS, Weikl TR. 2008. The protein folding problem. Annu Rev Biophys 37: 289-316.
17. Elkins PA, Ho YS, Smith WW, Janson CA, D'Alessio KJ, McQueney MS, Cummings MD, Romanic AM. 2002. Structure of the C-terminally truncated human ProMMP9, a gelatin-binding matrix metalloproteinase. Acta Crystallogr D Biol Crystallogr 58: 1182-1192.
18. Ellen A, Nollen A, Morimoto RI. 2002. Chaperoning signaling pathways: Molecular chaperones as stress-sensing 'heat shock' proteins. J Cell Sci 115: 2809-2816.
19. Fan JQ, Ishii S, Asano N, Suzuki Y. 1999. Accelerated transport and maturation of lysosomal alpha-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor. Nat Med 5: 112-115.
20. Ferrero S, Falleni M, Cattaneo M, Malferrari G, Canton C, Biagiotti L, Maggioni M, Nosotti M, Coggi G, Bosari S, Biunno I. 2006. SEL1L expression in non-small cell lung cancer. Hum Pathol 37: 505-512.
21. Fersht AR, Daggett V. 2002. Protein folding and unfolding at atomic resolution. Cell 108: 573-582.
22. Finkbeiner S, Cuervo AM, Morimoto RI, Muchowski PJ. 2006. Disease-modifying pathways in neurodegeneration. J Neurosci 26: 10349-10357.
23. Francisco AB, Singh R, Sha H, Yan X, Qi L, Lei X, Long Q. 2011. Haploid insufficiency of suppressor enhancer Lin12 1 like (SEL1L) predisposes mice to high fat diet-induced hyperglycemia. J Biol Chem Epub ahead of print, May 2.
24. Fujikake N, Nagai Y, Popiel HA, Okamoto Y, Yamaguchi M, Toda T. 2008. Heat shock transcription factor 1-activating compounds suppress polyglutamine-induced neurodegeneration through induction of multiple molecular chaperones. J Biol Chem 283: 26188-26197.
25. Garrido C, Brunet M, Didelot C, Zermati Y, Schmitt E, Kroemer G. 2006. Heat shock proteins 27 and 70: Anti-apoptotic proteins with tumorigenic properties. Cell Cycle 5: 2592-2601.
26. Grabowski GA. 2008. Treatment perspectives for the lysosomal storage diseases. Expert Opin Emerg Drugs 13: 197-211.
27. Granelli P, Cattaneo M, Ferrero S, Bottiglieri L, Bosari S, Fichera G, Biunno I. 2004. SEL1L and squamous cell carcinoma of the esophagus. Clin Cancer Res 10: 5857-5861.
28. Griciuc A, Aron L, Roux MJ, Klein R, Giangrande A, Ueffing M. 2010. Inactivation of VCP/ter94 suppresses retinal pathology caused by misfolded rhodopsin in Drosophila. PLoS Genet 6: e1001075.
29. Hartl FU, Hayer-Hartl M. 2009. Converging concepts of protein folding in vitro and in vivo. Nat Struct Mol Biol 16: 574-581.
30. Hegde RS, Ploegh HL. 2010. Quality and quantity control at the endoplasmic reticulum. Curr Opin Cell Biol 22: 437-446.
31. Herbst M, Wanker EE. 2007. Small molecule inducers of heat-shock response reduce polyQ-mediated huntingtin aggregation. A possible therapeutic strategy. Neurodegener Dis 4: 254-260.
32. Hersey P, Zhang XD. 2008. Adaptation to ER stress as a driver of malignancy and resistance to therapy in human melanoma. Pigment Cell Melanoma Res 21: 358-367.
33. Höhfeld J, Minami Y, Hartl FU. 2005. Hip, a novel cochaperone involved in the eukaryotic Hsc70/Hsp40 reaction cycle. Cell 83: 589-598.
34. Hutt D, Balch WE. 2010. Cell Biology. The proteome in balance. Science 329: 766-767.
35. Hutt DM, Herman D, Rodrigues AP, Noel S, Pilewski JM, Matteson J, Hoch B, Kellner W, Kelly JW, Schmidt A, Thomas PJ, Matsumura Y, Skach WR, Gentzsch M, Riordan JR, Sorscher EJ, Okiyoneda T, Yates JR 3rd, Lukacs GL, Frizzell RA, Manning G, Gottesfeld JM, Balch WE. 2010. Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis. Nat Chem Biol 6: 25-33.
36. Kalia SK, Kalia LV, McLean PJ. 2010. Molecular chaperones as rational drug targets for Parkinson's disease therapeutics. CNS Neurol Disord Drug Targets 9: 741-753.
37. Kalmar B, Novoselov S, Gray A, Cheetham ME, Margulis B, Greensmith L. 2008. Late stage treatment with arimoclomol delays disease progression and prevents protein aggregation in the SOD1 mouse model of ALS. J. Neurochem 107: 339-350.
38. Kelley LA, Sternberg MJ. 2009. Protein structure prediction on the Web: A case study using the Phyre server. Nat Protoc 4: 363-371.
39. Koong DFaAC. 2007. Irestatin, a potent inhibitor of IRE1 and the unfolded protein response, is a hypoxia-selective cytotoxin and impairs tumor growth. Journal of Clinical Oncology, ASCO Annual Meeting Proceedings (Post-Meeting Edition).
40. Kubelka J, Chiu TK, Davies DR, Eaton WA, Hofrichter J. 2006. Sub-microsecond protein folding. J Mol Biol 359: 546-553.
41. Loo TW, Bartlett MC, Clarke DM. 2008. Correctors promote folding of the CFTR in the endoplasmic reticulum. Biochem J 413: 29-36.
42. Luo GR, Le WD. 2010. Collective roles of molecular chaperones in protein degradation pathways associated with neurodegenerative diseases. Curr Pharm Biotechnol 11: 180-187.
43. Luthy L, Grutter MG, Mittl PR. 2002. The crystal structure of Helicobacter pylori cysteine-rich protein B reveals a novel fold for a penicillin-binding protein. J Biol Chem 277: 10187-10193.
44. Lüthy L, Grütter MG, Mittl PR. 2004. The crystal structure of Helicobacter cysteine-rich protein C at 2.0 A resolution: Similar peptide-binding sites in TPR and SEL1-like repeat proteins. J Mol Biol 340: 829-841.
45. Massey AC, Zhang C, Cuervo AM. 2006. Chaperone-mediated autophagy in aging and disease. Curr Top Dev Biol 73: 205-235.
46. McDonough H, Patterson C. 2003. CHIP: A link between the chaperone and proteasome systems. Cell Stress Chaperones 8: 303-308.
47. Meriin AB, Sherman MY. 2005. Role of molecular chaperones in neurodegenerative disorders. Int J Hyperthermia 21: 403-419.
48. Morimoto RI. 2008. Proteotoxic stress and inducible chaperone networks in neurodegenerative disease and aging. Genes Dev 22: 1427-1438.
49. Mu TW, Fowler DM, Kelly JW. 2008b. Partial restoration of mutant enzyme homeostasis in three distinct lysosomal storage disease cell lines by altering calcium homeostasis. PLoS Biol 6: e26.
50. Mu TW, Ong DS, Wang YJ, Balch WE, Yates JR 3rd, Segatori L, Kelly JW. 2008a. Chemical and biological approaches synergize to ameliorate protein-folding diseases. Cell 134: 769-781.
51. Orlandi R, Cattaneo M, Troglio F, Casalini P, Ronchini C, Menard S, Biunno I. 2002. SEL1L expression decreases breast tumor cell aggressiveness in vivo and in vitro. Cancer Res 62: 567-574.
52. Olzmann JA, Li L, Chin LS. 2008. Aggresome formation and neurodegenerative diseases: Therapeutic implications. Curr Med Chem 15: 47-60.
53. Pacey S, Banerji U, Judson I, Workman P. 2006. Hsp90 inhibitors in the clinic. Handb Exp Pharmacol 172: 331-358.
54. Park HJ, Mylvaganum M, McPherson A, Fewell SW, Brodsky JL, Lingwood CA. 2009. A soluble sulfogalactosyl ceramide mimic promotes Delta F508 CFTR escape from endoplasmic reticulum associated degradation. Chem Biol 16: 461-470.
55. Park HS, Cho SG, Kim CK, Hwang HS, Noh KT, Kim MS, Huh SH, Kim MJ, Ryoo K, Kim EK, Kang WJ, Lee JS, Seo JS, Ko YG, Kim S, Choi EJ. 2002. Heat shock protein hsp72 is a negative regulator of apoptosis signal-regulating kinase 1. Mol Cell Biol 22: 7721-7730.
56. Powers MV, Workman P. 2006. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors. Endocr Relat Cancer 13: S125-S135.
57. Prodromou C, Roe SM, O'Brien R, Ladbury JE, Piper PW, Pearl LH. 1997. Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone. Cell 90: 65-75.
58. Putcha P, Danzer KM, Kranich L, Scott A, Silinski M, Mabbett S, Hicks CD, Veal JM, Steed PM, Hyman BT, McLean PJ. 2010. Brain permeable small molecule inhibitors of Hsp90 prevent alpha-synuclein oligomer formation and rescue alpha synuclein-induced toxicity. J Pharmacol Exp Ther 332: 849-857.
59. Pyrko P, Schonthal AH, Hofman FM, Chen TC, Lee AS. 2007. The unfolded protein response regulator GRP78/BiP as a novel target for increasing chemosensitivity in malignant gliomas. Cancer Res 67: 9809-9816.
60. Ratajczak T, Carrello A, Mark PJ, Warner BJ, Simpson RJ, Moritz RL, House AK. 1993. The cyclophilin component of the unactivated estrogen receptor contains a tetratricopeptide repeat domain and shares identity with p59 (FKBP59). J Biol Chem 268: 13187-13192.
61. Redmann V, Oresic K, Tortorella LL, Cook JP, Lord M, Tortorella D. 2011. Dislocation of ricin toxin A chains in human cells utilizes selective cellular factors. J Biol Chem Epub ahead of print, Apr 28.
62. Ringe D, Petsko GA. 2009. What are pharmacological chaperones and why are they interesting? J Biol 8: 80.
63. Ron D, Walter P. 2007. Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol 8: 519-529.
64. Sarkar S, Davies JE, Huang Z, Tunnacliffe A, Rubinsztein DC. 2007. Trehalose, a novel mTOR-independent autophagy enhancer, accelerates the clearance of mutant huntingtin and alpha-synuclein. J Biol Chem 282: 5641-5652.
65. Sawkar AR, Cheng WC, Beutler E, Wong CH, Balch WE, Kelly JW. 2002. Chemical chaperones increase the cellular activity of N370S beta -glucosidase: A therapeutic strategy for Gaucher disease. Proc Natl Acad Sci USA 99: 15428-15433.
66. Scriven P, Coulson S, Haines R, Balasubramanian S, Cross S, Wyld L. 2009. Activation and clinical significance of the unfolded protein response in breast cancer. Br J Cancer 101: 1692-1698.
67. Scroggins BT, Robzyk K, Wang D, Marcu MG, Tsutsumi S, Beebe K, Cotter RJ, Felts S, Toft D, Karnitz L, Rosen N, Neckers L. 2007. An acetylation site in the middle domain of Hsp90 regulates chaperone function. Mol Cell 25: 151-159.
68. Shen HY, He JC, Wang Y, Huang QY, Chen JF. 2005. Geldanamycin induces heat shock protein 70 and protects against MPTP-induced dopaminergic neurotoxicity in mice. J Biol Chem 280: 39962-39969.
69. Sittler A, Lurz R, Lueder G, Priller J, Lehrach H, Hayer-Hartl MK, Hartl FU, Wanker EE. 2001. Geldanamycin activates a heat shock response and inhibits huntingtin aggregation in a cell culture model of Huntington's disease. Hum Mol Genet 10: 1307-1315.
70. Stanley AM, Carvalho P, Rapoport T. 2011. Recognition of an ERAD-L substrate analyzed by site-specific in vivo photocrosslinking. FEBS Lett 585: 1281-1286.
71. Supko JG, Hickman RL, Grever MR, Malspeis L. 1995. Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother Pharmacol 36: 305-315.
72. Takayama S, Reed JC. 2001. Molecular chaperone targeting and regulation by BAG family proteins. Nat Cell Biol 3: E237-E241.
73. Tanaka M, Machida Y, Niu S, Ikeda T, Jana NR, Doi H, Kurosawa M, Nekooki M, Nukina N. 2004. Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease. Nat Med 10: 148-154.
74. Turcotte S, Giaccia AJ. 2010. Targeting cancer cells through autophagy for anticancer therapy. Curr Opin Cell Biol 22: 246-251.
75. Udgaonkar JB. 2008. Multiple routes and structural heterogeneity in protein folding. Annu Rev Biophys 37: 489-510.
76. Vij N, Fang S, Zeitlin PL. 2006. Selective inhibition of endoplasmic reticulum-associated degradation rescues DeltaF508-cystic fibrosis transmembrane regulator and suppresses interleukin-8 levels: Therapeutic implications. J Biol Chem 281: 17369-17378.
77. Voellmy R. 2006. Feedback regulation of the heat shock response. Handb Exp Pharmacol 172: 43-68.
78. Voelz VA, Bowman GR, Beauchamp K, Pande VS. 2010. Molecular simulation of ab initio protein folding for a millisecond folder NTL9 (1-39). J Am Chem Soc 132: 1526-1528.
79. Wang Y, Bartlett MC, Loo TW, Clarke DM. 2006. Specific rescue of cystic fibrosis transmembrane conductance regulator processing mutants using pharmacological chaperones. Mol Pharmacol 70: 297-302.
80. Wang Y, Loo TW, Bartlett MC, Clarke DM. 2007. Additive effect of multiple pharmacological chaperones on maturation of CFTR processing mutants. Biochem J 406: 257-263.
81. Whitesell L, Lindquist S. 2009. Inhibiting the transcription factor HSF1 as an anticancer strategy. Expert Opin Ther Targets 13: 469-478.
82. Whitesell L, Lindquist SL. 2005. HSP90 and the chaperoning of cancer. Nat Rev Cancer 5: 761-772.
83. Yu Z, Sawkar AR, Kelly JW. 2007. Pharmacologic chaperoning as a strategy to treat Gaucher disease. FEBS J 274: 4944-4950.
84. Zhang YQ, Sarge KD. 2007. Celastrol inhibits polyglutamine aggregation and toxicity though induction of the heat shock response. J Mol Med 85: 1421-1428.